HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Garnier Nutritioniste signs new face

This article was originally published in The Rose Sheet

Executive Summary

L'Oreal brand says model/actress Bridget Moynahan "embodies its vision of natural beauty" and is "the perfect canvas to showcase Garnier's UltraLift products," which target the anti-aging needs of women in their 30s and 40s. Print and TV campaigns featuring Moynahan will launch in July 2010, company says. Moynahan has graced the cover of Glamour, Vogue and other fashion magazines, enjoyed a recurring role on television series "Sex & the City" and appeared in such films as "Serendipity," "The Sum of All Fears" and "The Recruit." Currently she is shooting "Battle: Los Angeles" and will star in the 2010 film "Ramona and Beezus." Other Garnier spokesmodels include Sarah Jessica Parker, Bar Rafaeli and Alana de la Garza

You may also be interested in...

Sanofi Bets Big On IO With Synthorx Buy

The French drugmaker is paying $2.5bn to get hold of THOR-707 which it claims has the potential to become the best-in-class IL-2 therapeutic for solid tumors, thanks to improved pharmacology and less frequent dosing.

Global Industry Hails Bioequivalence Progress

For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.

Generics Leaders Trade Places At The Top

In 2019, Mylan moved up to become the world’s leading generics, biosimilars and OTC player, according to Informa Pharma Intelligence’s latest global rankings. Sandoz has surpassed troubled Teva into second place but is set to surrender that position following the sale of its US solid-dose and dermatology business to India’s Aurobindo.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts